Jacob Agamasu, MD
Cardiovascular Disease · Lake Mary, FLNPI 1194774604
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 61.8% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $2,031 and has fallen 63.7% since, to $737 in 2025.
Across 157 payments — averaging $68.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Abiomed$1K
- Cardiva Medical, Inc.$338
- Novartis$309
- Amgen$278
- Johnson & Johnson$253
- plus $2K from 23 others
What the payments were for
- Food & beverage$10,748100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 65 | $6,640 |
| Abiomed | 10 | $1,193 |
| Cardiva Medical, Inc. | 4 | $338 |
| Novartis | 16 | $309 |
| Amgen | 5 | $278 |
| Johnson & Johnson | 9 | $253 |
| Medtronic(2 entities) | 5 | $231 |
| Boehringer Ingelheim | 6 | $214 |
| Inari Medical, Inc. | 1 | $212 |
| Novo Nordisk | 3 | $161 |
| Philips North America LLC | 1 | $130 |
| Portola Pharmaceuticals, LLC | 5 | $127 |
| Roche Diagnostics Corporation | 2 | $117 |
| Boston Scientific | 2 | $101 |
| Kestra Medical Technology Services, Inc. | 3 | $68 |
| AstraZeneca | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Lilly USA, LLC | 2 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $37 |
| Angiodynamics, Inc. | 1 | $33 |
| Merck | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Convatec Inc. | 1 | $19 |
| GE HealthCare | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$2,048
- Confirm Rx$1,016
- Impella$847
- Quadra Assura CRT Defibrillator$808
- ENSITE PRECISION$400
- JOT DX$340
- Unify Assura CRT Defibrillator$303
- Assurity Pacemaker$292
- Allure CRT Pacemaker$251
- Repatha$231
- CT THROMBECTOMY SYSTEM KIT$212
- FLOWTRIEVER CATHETER, S$212
- (4067) Tack Endo Sys BTK$130
- Ensite Cardiac Mapping System$124
- XARELTO$115
- Reveal LINQ$105
- JARDIANCE$104
How this compares
$10,748 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 226 | $267,898 |
| EntrestoSacubitril/Valsartan | 79 | $98,553 |
| XareltoRivaroxaban | 51 | $36,825 |
| MounjaroTirzepatide | 33 | $33,947 |
| OzempicSemaglutide | 26 | $29,002 |
| Ranolazine ErRanolazine | 26 | $4,484 |
| Bisoprolol Fumarate | 84 | $2,425 |
| Metoprolol Succinate | 181 | $2,126 |
| Rosuvastatin Calcium | 143 | $1,541 |
| Amlodipine Besylate | 256 | $1,337 |
| Atorvastatin Calcium | 124 | $1,208 |
| Losartan Potassium | 101 | $1,175 |
| ClopidogrelClopidogrel Bisulfate | 93 | $991 |
| Metoprolol Tartrate | 166 | $877 |
| Amiodarone Hcl | 26 | $603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $267,898226 claims |
| NovartisEntresto | $309 | $98,55379 claims |
| Johnson & JohnsonXarelto | $253 | $36,82551 claims |
| Lilly USA, LLCMounjaro | $38 | $33,94733 claims |
| Novo NordiskOzempic | $161 | $29,00226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Lake Mary
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.